Overview

Reversal of Dabigatran With Prothrombin Complex Concentrate

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether Prothrombin Complex Concentrate (PCC) is effective in reversing the anticoagulant effect of Dabigatran, as assessed by two modified skin-bleeding tests.
Phase:
Phase 2
Details
Lead Sponsor:
University Medical Center Groningen
Collaborators:
Boehringer Ingelheim
CSL Behring
Treatments:
Dabigatran
Thrombin